Gliclazide

This classification denotes an anti-diabetic agent with the molecular formula C15H21N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) G4PX8C4HKV, chemically known as urea, 1-(hexahydrocyclopenta(c)pyrrol-2(1h)-yl)-3-(p-tolylsulfonyl)- but more generally known as gliclazide, which bears US NIH Compound Identifier 3475. European Medicines Agency schedules Gliclazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07921MIG. The term GLICLAZIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 25 , No. 10 1971, List 11) WHO schedules gliclazide in its Anatomical Therapeutic Chemical (ATC) Classification. GLICLAZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule gliclazide under HS 29350090 and SITC 51580. As of Q4 2014, GLICLAZIDE remains US FDA's Preferred Term for this commodity. Gliclazide bears US NLM identifiers UMLS ID C0017631 and NCI Concept Code C87618. SMILES: S(=O)(=O)(NC(=O)NN1CC2C(CCC2)C1)C1CCC(CC1)C.